ProKidney to Participate in the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from June 4 – 6, 2024 in New York, NY. 

The ProKidney management team will host one-on-one meetings during the event. Interested investors should contact their Jefferies representative to schedule meetings.

About ProKidneyProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program. For more information, please visit www.prokidney.com.

Investor Contacts:

ProKidneyEthan Holdaway [email protected]

LifeSci Advisors, LLCDaniel Ferry [email protected]

You May Also Be Interested In

• Ozari Health Offers Compounded Semaglutide From $86 Per Month and Tirzepatide From $125 Per Month on Nationwide Telehealth Platform as Updated 2026 GLP-1 Pricing Data Goes Live
• Mountain Mike’s Pizza Proudly Kicks Off Ninth Season as the Official Pizza of the San Francisco 49ers
• JustinMendez.ai Launches Free Agentic Engineering Course and AI Workshop for Business Leaders